Your browser doesn't support javascript.
Long COVID and the cardiovascular system - elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: A joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial & Pericardial Diseases.
Gyöngyösi, Mariann; Alcaide, Pilar; Asselbergs, Folkert W; Brundel, Bianca J J M; Camici, Giovanni G; da Costa Martins, Paula; Ferdinandy, Péter; Fontana, Marianna; Girao, Henrique; Gnecchi, Massimiliano; Gollmann-Tepeköylü, Can; Kleinbongard, Petra; Krieg, Thomas; Madonna, Rosalinda; Paillard, Melanie; Pantazis, Antonis; Perrino, Cinzia; Pesce, Maurizio; Schiattarella, Gabriele G; Sluijter, Joost P G; Steffens, Sabine; Tschöpe, Carsten; Van Linthout, Sophie; Davidson, Sean M.
  • Gyöngyösi M; Division of Cardiology, 2nd Department of Internal Medicine, Medical University of Vienna, Vienna, Austria.
  • Alcaide P; Department of Immunology, Tufts University School of Medicine, Boston, MA, USA.
  • Asselbergs FW; Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Brundel BJJM; Health Data Research UK and Institute of Health Informatics, University College London, London, United Kingdom.
  • Camici GG; Department of Physiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands.
  • da Costa Martins P; Center for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
  • Ferdinandy P; University Heart Center, Department of Cardiology, University Hospital, Zurich, Switzerland.
  • Fontana M; Department of Cardiology, CARIM School for Cardiovascular Diseases, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, Netherlands.
  • Girao H; Department of Molecular Genetics, Faculty of Sciences and Engineering, Maastricht University, Maastricht, The Netherlands.
  • Gnecchi M; Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.
  • Gollmann-Tepeköylü C; Pharmahungary Group, Szeged, Hungary.
  • Kleinbongard P; Royal Free Hospital London, Division of Medicine, University College London, London, UK.
  • Krieg T; Center for Innovative Biomedicine and Biotechnology (CIBB), Clinical Academic Centre of Coimbra (CACC), Faculty of Medicine, Univ Coimbra, Institute for Clinical and Biomedical Research (iCBR), Coimbra, Portugal.
  • Madonna R; Department of Molecular Medicine, Unit of Cardiology, University of Pavia.
  • Paillard M; Unit of Translational Cardiology, Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Pantazis A; Department of Cardiac Surgery, Medical University of Innsbruck, Austria.
  • Perrino C; Institut für Pathophysiologie, Westdeutsches Herz- und Gefäßzentrum, Universitätsklinikum Essen, Essen, Germany.
  • Pesce M; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Schiattarella GG; Department of Pathology, Institute of Cardiology, University of Pisa, Pisa, Italy.
  • Sluijter JPG; Laboratoire CarMeN-équipe IRIS, INSERM, INRA, Université Claude Bernard Lyon-1, INSA-Lyon, Univ- Lyon, 69500 Bron, France.
  • Steffens S; National Heart and Lung Institute, Imperial College London, London, United Kingdom; Cardiovascular Research Centre at Royal Brompton and Harefield Hospitals, London, United Kingdom.
  • Tschöpe C; Department of Advanced Biomedical Sciences, Federico II University, Via Pansini 5, 80131 Naples.
  • Van Linthout S; Unità di Ingegneria Tissutale cardiovascolare, Centro Cardiologico Monzino, IRCCS.
  • Davidson SM; Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.
Cardiovasc Res ; 2022 Jul 25.
Article in English | MEDLINE | ID: covidwho-2261754
ABSTRACT
Long COVID has become a world-wide, non-communicable epidemic, caused by long-lasting multi-organ symptoms that endure for weeks or months after SARS-CoV-2 infection has already subsided. This scientific document aims to provide insight into the possible causes and therapeutic options available for the cardiovascular manifestations of long COVID. In addition to chronic fatigue, which is a common symptom of long COVID, patients may present with chest pain, ECG abnormalities, postural orthostatic tachycardia, or newly developed supraventricular or ventricular arrhythmias. Imaging of the heart and vessels has provided evidence of chronic, post-infectious peri-myocarditis with consequent left or right ventricular failure, arterial wall inflammation or micro-thrombosis in certain patient populations. Better understanding of the underlying cellular and molecular mechanisms of long COVID will aid in the development of effective treatment strategies for its cardiovascular manifestations. A number of mechanisms have been proposed, including those involving direct effects on the myocardium, micro-thrombotic damage to vessels or endothelium, or persistent inflammation. Unfortunately, existing circulating biomarkers, coagulation and inflammatory markers, are not highly predictive for either the presence or outcome of long COVID when measured 3 months after SARS-CoV-2 infection. Further studies are needed to understand underlying mechanisms, identify specific biomarkers and guide future preventive strategies or treatments to address long COVID and its cardiovascular sequelae.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Topics: Long Covid Language: English Year: 2022 Document Type: Article Affiliation country: Cvr

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Randomized controlled trials Topics: Long Covid Language: English Year: 2022 Document Type: Article Affiliation country: Cvr